OmniScience and INmune Bio partner to enhance decision-making in Alzheimer's clinical trials using Vivo's genAI-powered platform.

Quiver AI Summary

OmniScience and INmune Bio have announced a partnership aimed at enhancing operations for INmune Bio's global Phase 2 clinical trial for Alzheimer's disease using OmniScience's innovative product, Vivo. Vivo is a genAI-powered control tower designed to centralize and analyze vast amounts of clinical data in real-time, significantly improving decision-making and operational efficiency in clinical trials. It integrates data from multiple sources, enabling teams to identify issues, visualize patient outcomes, and make timely, informed decisions, thereby accelerating trial timelines and enhancing patient safety. Currently, INmune Bio is conducting an overenrolled trial with 208 patients, and they expect to release preliminary cognitive results in mid-2025. Both companies see the potential of Vivo to transform the clinical trial process, making it more efficient and data-driven, ultimately aiming to deliver answers and treatments to patients faster.

Potential Positives

• Partnership with INmune Bio to enhance data analysis in clinical trials demonstrates OmniScience's commitment to innovation in the biotechnology sector.
• Vivo's introduction is set to improve decision-making capabilities, potentially leading to faster and more effective clinical trial outcomes.
• The technology has received recognition, being awarded top honors at the 2024 Innovation Showcase, highlighting its industry impact and credibility.
• Vivo's advanced cognitive architecture promises to unify and streamline clinical trial operations, reducing reliance on traditional analysis methods.

Potential Negatives

• Dependence on unproven technology: The reliance on Vivo and its genAI capabilities to analyze complex clinical data may pose risks if the technology does not perform as expected, potentially jeopardizing the trial's outcomes.
• Regulatory uncertainty: The press release highlights that INmune Bio's product candidates are still in clinical trials and have not yet received FDA approval, introducing significant risk regarding their future commercialization and efficacy.
• Forward-looking statements caution: The numerous forward-looking statements regarding trial success and technology performance may indicate inherent uncertainties that could undermine investor confidence if outcomes diverge from expectations.

FAQ

What is the partnership between OmniScience and INmune Bio about?

The partnership aims to enhance INmune Bio's Phase 2 Alzheimer's disease clinical trial using OmniScience's genAI-powered product, Vivo, to improve data analysis and decision-making.

How does Vivo enhance clinical trial operations?

Vivo centralizes data from multiple sources in real time, enabling clinical teams to make faster, data-driven decisions and improve patient safety and outcomes.

What clinical trial is currently being supported by Vivo?

Vivo is currently supporting INmune Bio's Phase 2 Alzheimer's disease clinical trial, known as the AD02 trial, which involves 208 patients.

What are the benefits of using Vivo in clinical trials?

Vivo improves data quality, enhances visualization of outcomes, provides real-time insights, and reduces reliance on manual data analysis methods.

When will INmune Bio release results from the AD02 trial?

INmune Bio plans to release top-line cognitive results from the AD02 trial in the second quarter of 2025.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$INMB Insider Trading Activity

$INMB insiders have traded $INMB stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.

Here's a breakdown of recent trading of $INMB stock by insiders over the last 6 months:

• DAVID J MOSS (Chief Financial Officer) has traded it 2 times. They made 2 purchases, buying 17,690 shares and 0 sales.
• RAYMOND JOSEPH TESI (President and CEO) purchased 15,380 shares.
• SCOTT JUDA purchased 5,000 shares.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$INMB Hedge Fund Activity

We have seen 46 institutional investors add shares of $INMB stock to their portfolio, and 25 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• CVI HOLDINGS, LLC added 596,372 shares (+inf%) to their portfolio in Q2 2024
• PRAETORIAN PR LLC added 295,800 shares (+61.0%) to their portfolio in Q3 2024
• RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC. added 141,904 shares (+62.4%) to their portfolio in Q3 2024
• BLACKROCK, INC. added 126,573 shares (+15.6%) to their portfolio in Q3 2024
• MILLENNIUM MANAGEMENT LLC added 109,834 shares (+118.5%) to their portfolio in Q3 2024
• RENAISSANCE TECHNOLOGIES LLC added 107,200 shares (+inf%) to their portfolio in Q3 2024
• VANGUARD GROUP INC added 92,413 shares (+14.7%) to their portfolio in Q3 2024

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

Vivo Empowers Clinical Development Teams to Accelerate Decision-making and Analyses in Clinical Trials for Improved Outcomes

HOUSTON and BOCA RATON, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) --

OmniScience

and

INmune Bio

(

NASDAQ: INMB

) today announced a pioneering partnership to revolutionize operations for INmune Bio's global Phase 2 Alzheimer's disease (AD) clinical trial (the "AD02 trial") using OmniScience's flagship product, Vivo, an industry-first, genAI-powered control tower designed specifically for centralizing and analyzing vast clinical data in real time. This solution represents a innovative approach to clinical research, delivering immediate insights that enhance decision-making and transform traditional, time-consuming trial management.

Vivo securely unifies data across sources including electronic data capture (EDC), clinical trial management systems (CTMS), patient-reported outcomes (PROs)/clinical outcome assessments (COAs), labs, sensors/wearables, safety databases, and more. With fully integrated data, Vivo goes beyond dashboard visualizations to enable clinical trial teams to improve their decision-making, accelerate timelines, enhance patient safety, and ultimately improve health outcomes. Designed with explainability and interpretability at its core, Vivo ensures that every generated insight is supported by clear, traceable rationale grounded in data and clinical context. Its advanced cognitive architecture combines ontological knowledge of trial protocols with domain-specific clinical expertise, enabling qualitative and quantitative reasoning at scale.

INmune Bio

recently announced

it completed randomization of patients for its blinded AD02 trial for patients with early AD and biomarkers of elevated neuroinflammation. The trial overenrolled with a total of 208 patients, 56% of whom were categorized as mild AD and 44% as mild cognitive impairment. INmune Bio plans to release top-line cognitive results in the second quarter of 2025.

"A global trial of this size is vast, and Vivo will be critical in our ability to analyze cognitive results," stated Tara Lehner, INmune Bio's VP of Clinical Operations. "With genAI provided by Vivo, we can amplify our clinical teams' capabilities, turning complex data into actionable insights at unprecedented speed, which means we can get answers—and treatments—to patients faster."

INmune and OmniScience partnered throughout Vivo's product development and have completed the first phase of Vivo's roll-out to INmune's clinical development team. Throughout the initial rollout, significant beneficial findings include:

• 
  Improved data quality through Vivo's automatic identification of data discrepancies
  
• 
  Enhanced visualization of COAs, supporting identification of outliers and better understanding of population distributions
  
• 
  Real-time answers, supporting decisions on patient enrollment criteria, even while the patient is in the clinic
  
• 
  Reduced reliance on time-consuming spreadsheet-based data analysis, improving collaboration between clinical and executive teams
  

"OmniScience and INmune Bio share a vision to transform how clinical trial teams engage with data – transforming data into knowledge in real time and informing decisions that increase the probability of success," shared Angela Holmes, CEO of OmniScience. "As our partnership moves forward, we're gaining further insights from the INmune team that we can integrate into Vivo's roadmap. We look forward to our continued mutual success."

"The future of clinical trials demands smarter solutions, and Vivo embodies this shift," explained Michael Bell, VP of Product, OmniScience. "Through this collaboration, INmune Bio provides continuous feedback that enables OmniScience's development team to evolve Vivo. This hands-on approach builds confidence among users, who see firsthand how genAI can rapidly turn data into answers and transform their day-to-day workflows."

About OmniScience Inc.

OmniScience

is a trusted partner to leading life science organizations, advancing clinical R&D missions through unparalleled expertise in clinical data science. We believe in a future where all clinical trial data can be unified and translated into knowledge in real time.

Our expert team has created Vivo, the first and only company in the world to enable GenAI as a control tower, offering on demand insights into live unified clinical trial data. No spreadsheets, no SQL queries, no emails. Vivo revolutionizes the way pharma manages clinical trials and employs generative AI, with the industry's first gen AI assistant for clinical trial operations. Vivo is more than just a platform – it's your new favorite clinical development colleague, poised to transform clinical trial operation teams' day-to-day workflow and ability to optimize trial insights with generative AI. Vivo was recently

awarded top honors

at the Innovation Showcase at the November 2024 CNS Summit as well as the 2024 Innovation Network Gathering Whale Tank competition.

To discuss how OmniScience can support your clinical trials, please visit



or reach us at

hello@omniscience.bio

or on

LinkedIn

.

About INmune Bio Inc.

INmune Bio Inc.

is a publicly traded (

NASDAQ: INMB

), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03), Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit



.

Forward Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03, XPro1595 (XPro), and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

For OmniScience:

Media Contact:
Sean Leous
ICR Healthcare

Sean.leous@icrhealthcare.com

646-866-4012

For INmune Bio Inc.:

David Moss
Co-founder and Chief Financial Officer
(858) 964-3720

info@inmunebio.com



Daniel Carlson
Head of Investor Relations
(415) 509-4590

dcarlson@inmunebio.com

Investor Contact:
Mike Moyer
Managing Director – LifeSci Advisors

mmoyer@lifesciadvisors.com